Significantly increased risk for tardive dyskinesia seen with doses >75 mg\/day at last prescription and as maximum dose<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Jan. 17, 2025 (HealthDay News) — Antipsychotics at doses >75 mg\/day are associated with an increased risk for tardive dyskinesia (TD), according to a study recently published in the Journal of Clinical Psychopharmacology<\/em>.<\/p>\n Maki Gouda, from the Mitsubishi Tanabe Pharma Corporation in Osaka, Japan, and colleagues examined the association between antipsychotic doses and the risk for TD in clinical practice in a population of patients aged 15 years or older with a diagnosis of schizophrenia, depression, or bipolar disorder. Patients newly diagnosed with TD were categorized as cases and were matched with a control group in a 1:10 ratio.<\/p>\n The analysis population included 58,452 patients; 80 of these patients were identified as TD cases. The researchers found that doses >75 mg\/day at the last prescription and as the maximum dose before the date of TD diagnosis were associated with a significantly increased risk for TD. In post-hoc analyses, there was a significant association between doses \u2265300 mg\/day versus \u226475 and >75 to <300 mg\/day and the risk for TD. The odds ratios were 3.40 and 3.50 when comparing \u2265300 mg\/day with >75 to <300 mg\/day at the last prescription and as the maximum dose before first diagnosis of TD, respectively.<\/p>\n “The prescription of high dose was associated with an increased risk of TD, and the highest risk was observed in the group receiving >300 mg\/day,” the authors write. “Therefore, it is crucial to consider the potential risks of TD and to carefully monitor patients receiving antipsychotic treatment.”<\/p>\n Several authors disclosed ties to pharmaceutical companies, including the Mitsubishi Tanabe Pharma Corporation, which funded the study.<\/p>\n